- Home
- SBFM vs KLTO Comparison
SBFM vs KLTO Comparison
Compare SBFM & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- KLTO
- Stock Information
- Founded
- SBFM 2006
- KLTO 2019
- Country
- SBFM United States
- KLTO United States
- Employees
- SBFM N/A
- KLTO N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- SBFM Health Care
- KLTO
- Exchange
- SBFM Nasdaq
- KLTO NYSE
- Market Cap
- SBFM 4.9M
- KLTO 5.0M
- IPO Year
- SBFM N/A
- KLTO N/A
- Fundamental
- Price
- SBFM $1.55
- KLTO $0.16
- Analyst Decision
- SBFM Strong Buy
- KLTO
- Analyst Count
- SBFM 1
- KLTO 0
- Target Price
- SBFM $15.00
- KLTO N/A
- AVG Volume (30 Days)
- SBFM 4.3M
- KLTO 152.3K
- Earning Date
- SBFM 05-19-2025
- KLTO 05-15-2025
- Dividend Yield
- SBFM N/A
- KLTO N/A
- EPS Growth
- SBFM N/A
- KLTO N/A
- EPS
- SBFM N/A
- KLTO N/A
- Revenue
- SBFM $34,874,283.00
- KLTO N/A
- Revenue This Year
- SBFM $192.48
- KLTO N/A
- Revenue Next Year
- SBFM N/A
- KLTO N/A
- P/E Ratio
- SBFM N/A
- KLTO N/A
- Revenue Growth
- SBFM 44.75
- KLTO N/A
- 52 Week Low
- SBFM $1.17
- KLTO $0.11
- 52 Week High
- SBFM $33.60
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- SBFM 44.81
- KLTO N/A
- Support Level
- SBFM $1.17
- KLTO N/A
- Resistance Level
- SBFM $1.59
- KLTO N/A
- Average True Range (ATR)
- SBFM 0.19
- KLTO 0.00
- MACD
- SBFM 0.03
- KLTO 0.00
- Stochastic Oscillator
- SBFM 52.84
- KLTO 0.00
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.